Noteworthy Fetal stem cell transplantation ramps up

WASHINGTON - The Food and Drug Administration expects a dramatic increase in the number of in utero stem-cell transplants using human subjects, according to a report by the Center for Biologics Evaluation and Research.

At last week's meeting of the Biological Response Modifiers Advisory Committee (BRMAC), CBER reported that it expects to receive applications for Phase I trials involving 60 patients in the next two years in which hematopoietic cells will be injected into human fetuses, far more than the some 17 human subjects involved in such protocols in the last 10 years.